J&J signs on Xen­cor for a $100M li­cens­ing deal tar­get­ing CD20, look­ing to press its ad­van­tage in bis­pecifics

With a re­cent ap­proval for lung can­cer bis­pe­cif­ic ami­van­tam­ab, J&J is look­ing to build a fran­chise in that space with a grow­ing crop of drugs in the pipeline. The drug gi­ant has now tapped a fa­mil­iar part­ner to dri­ve that work ahead, and the pair is go­ing af­ter a well-known tar­get.

J&J’s Janssen unit has inked a li­cens­ing deal worth $100 mil­lion in up­front cash and $25 mil­lion in eq­ui­ty for glob­al li­cens­ing rights to Xen­cor’s CD20/CD3 bis­pe­cif­ic an­ti­body plam­o­tam­ab cur­rent­ly in Phase I test­ing against B cell ma­lig­nan­cies, the com­pa­nies said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER